Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma

Sunitinib, a multitargeted receptor tyrosine kinase inhibitor including vascular endothelial growth factor, has been widely used as a first‐line treatment against metastatic renal cell carcinoma (mRCC). However, mRCC often acquires resistance to sunitinib, rendering it difficult to treat with this a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuroshima, Kazuki, Yoshino, Hirofumi, Okamura, Shunsuke, Tsuruda, Masafumi, Osako, Yoichi, Sakaguchi, Takashi, Sugita, Satoshi, Tatarano, Shuichi, Nakagawa, Masayuki, Enokida, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226215/
https://www.ncbi.nlm.nih.gov/pubmed/32232883
http://dx.doi.org/10.1111/cas.14395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226215/
https://www.ncbi.nlm.nih.gov/pubmed/32232883
http://dx.doi.org/10.1111/cas.14395

Ejemplares similares